Park, Hanla A. http://orcid.org/0000-0001-8055-3729
Neumeyer, Sonja
Michailidou, Kyriaki
Bolla, Manjeet K.
Wang, Qin
Dennis, Joe http://orcid.org/0000-0003-4591-1214
Ahearn, Thomas U.
Andrulis, Irene L.
Anton-Culver, Hoda
Antonenkova, Natalia N.
Arndt, Volker
Aronson, Kristan J.
Augustinsson, Annelie http://orcid.org/0000-0003-3415-0536
Baten, Adinda
Beane Freeman, Laura E.
Becher, Heiko
Beckmann, Matthias W.
Behrens, Sabine
Benitez, Javier
Bermisheva, Marina
Bogdanova, Natalia V.
Bojesen, Stig E.
Brauch, Hiltrud
Brenner, Hermann http://orcid.org/0000-0002-6129-1572
Brucker, Sara Y.
Burwinkel, Barbara
Campa, Daniele
Canzian, Federico http://orcid.org/0000-0002-4261-4583
Castelao, Jose E.
Chanock, Stephen J.
Chenevix-Trench, Georgia
Clarke, Christine L.
Børresen-Dale, Anne-Lise
Grenaker Alnæs, Grethe I.
Sahlberg, Kristine K.
Ottestad, Lars
Kåresen, Rolf
Schlichting, Ellen
Holmen, Marit Muri
Sauer, Toril
Haakensen, Vilde
Engebråten, Olav
Naume, Bjørn
Fosså, Alexander
Kiserud, Cecile E.
Reinertsen, Kristin V.
Helland, Åslaug
Riis, Margit
Geisler, Jürgen
Conroy, Don M.
Couch, Fergus J.
Cox, Angela http://orcid.org/0000-0002-5138-1099
Cross, Simon S.
Czene, Kamila
Daly, Mary B.
Devilee, Peter http://orcid.org/0000-0002-8023-2009
Dörk, Thilo
dos-Santos-Silva, Isabel
Dwek, Miriam
Eccles, Diana M.
Eliassen, A. Heather
Engel, Christoph
Eriksson, Mikael
Evans, D. Gareth
Fasching, Peter A. http://orcid.org/0000-0003-4885-8471
Flyger, Henrik
Fritschi, Lin
García-Closas, Montserrat
García-Sáenz, José A.
Gaudet, Mia M.
Giles, Graham G.
Glendon, Gord
Goldberg, Mark S.
Goldgar, David E.
González-Neira, Anna
Grip, Mervi
Guénel, Pascal
Hahnen, Eric
Haiman, Christopher A.
Håkansson, Niclas
Hall, Per
Hamann, Ute
Han, Sileny
Harkness, Elaine F. http://orcid.org/0000-0001-6625-7739
Hart, Steven N. http://orcid.org/0000-0001-7714-2734
He, Wei
Heemskerk-Gerritsen, Bernadette A. M. http://orcid.org/0000-0002-9724-6693
Hopper, John L.
Hunter, David J.
Clarke, Christine
Marsh, Deborah
Scott, Rodney
Baxter, Robert
Yip, Desmond
Carpenter, Jane
Davis, Alison
Pathmanathan, Nirmala
Simpson, Peter
Graham, Dinny
Sachchithananthan, Mythily
Amor, David
Andrews, Lesley
Antill, Yoland
Balleine, Rosemary
Beesley, Jonathan
Bennett, Ian
Bogwitz, Michael
Botes, Leon
Brennan, Meagan
Brown, Melissa
Buckley, Michael
Burke, Jo
Butow, Phyllis
Caldon, Liz
Campbell, Ian
Chauhan, Deepa
Chauhan, Manisha
Chenevix-Trench, Georgia
Christian, Alice
Cohen, Paul
Colley, Alison
Crook, Ashley
Cui, James
Cummings, Margaret
Dawson, Sarah-Jane
DeFazio, Anna
Delatycki, Martin
Dickson, Rebecca
Dixon, Joanne
Edkins, Ted
Edwards, Stacey
Farshid, Gelareh
Fellows, Andrew
Fenton, Georgina
Field, Michael
Flanagan, James
Fong, Peter
Forrest, Laura
Fox, Stephen
French, Juliet
Friedlander, Michael
Gaff, Clara
Gattas, Mike
George, Peter
Greening, Sian
Harris, Marion
Hart, Stewart
Hayward, Nick
Hopper, John
Hoskins, Cass
Hunt, Clare
James, Paul
Jenkins, Mark
Kidd, Alexa
Kirk, Judy
Koehler, Jessica
Kollias, James
Lakhani, Sunil
Lawrence, Mitchell
Lindeman, Geoff
Lipton, Lara
Lobb, Liz
Mann, Graham
Marsh, Deborah
McLachlan, Sue Anne
Meiser, Bettina
Milne, Roger
Nightingale, Sophie
O’Connell, Shona
O’Sullivan, Sarah
Ortega, David Gallego
Pachter, Nick
Patterson, Briony
Pearn, Amy
Phillips, Kelly
Pieper, Ellen
Rickard, Edwina
Robinson, Bridget
Saleh, Mona
Salisbury, Elizabeth
Saunders, Christobel
Saunus, Jodi
Scott, Rodney
Scott, Clare
Sexton, Adrienne
Shelling, Andrew
Simpson, Peter
Southey, Melissa
Spurdle, Amanda
Taylor, Jessica
Taylor, Renea
Thorne, Heather
Trainer, Alison
Tucker, Kathy
Visvader, Jane
Walker, Logan
Williams, Rachael
Winship, Ingrid
Young, Mary Ann
Jager, Agnes
Jakubowska, Anna http://orcid.org/0000-0002-5650-0501
John, Esther M.
Jung, Audrey
Kaaks, Rudolf
Kapoor, Pooja Middha http://orcid.org/0000-0001-5503-8215
Keeman, Renske
Khusnutdinova, Elza
Kitahara, Cari M.
Koppert, Linetta B.
Koutros, Stella
Kristensen, Vessela N.
Kurian, Allison W. http://orcid.org/0000-0002-6175-9470
Lacey, James
Lambrechts, Diether
Le Marchand, Loic
Lo, Wing-Yee
Lubiński, Jan
Mannermaa, Arto
Manoochehri, Mehdi
Margolin, Sara
Martinez, Maria Elena
Mavroudis, Dimitrios
Meindl, Alfons
Menon, Usha
Milne, Roger L.
Muranen, Taru A.
Nevanlinna, Heli
Newman, William G. http://orcid.org/0000-0002-6382-4678
Nordestgaard, Børge G.
Offit, Kenneth
Olshan, Andrew F.
Olsson, Håkan
Park-Simon, Tjoung-Won
Peterlongo, Paolo http://orcid.org/0000-0001-6951-6855
Peto, Julian http://orcid.org/0000-0002-1685-8912
Plaseska-Karanfilska, Dijana
Presneau, Nadege
Radice, Paolo
Rennert, Gad
Rennert, Hedy S.
Romero, Atocha
Saloustros, Emmanouil
Sawyer, Elinor J. http://orcid.org/0000-0001-8285-4111
Schmidt, Marjanka K.
Schmutzler, Rita K.
Schoemaker, Minouk J.
Schwentner, Lukas
Scott, Christopher http://orcid.org/0000-0003-1340-0647
Shah, Mitul
Shu, Xiao-Ou
Simard, Jacques
Smeets, Ann http://orcid.org/0000-0002-5091-6602
Southey, Melissa C.
Spinelli, John J.
Stevens, Victoria
Swerdlow, Anthony J.
Tamimi, Rulla M.
Tapper, William J.
Taylor, Jack A.
Terry, Mary Beth
Tomlinson, Ian http://orcid.org/0000-0003-3037-1470
Troester, Melissa A.
Truong, Thérèse http://orcid.org/0000-0002-2943-6786
Vachon, Celine M.
van Veen, Elke M.
Vijai, Joseph
Wang, Sophia
Wendt, Camilla
Winqvist, Robert
Wolk, Alicja
Ziogas, Argyrios
Dunning, Alison M.
Pharoah, Paul D. P. http://orcid.org/0000-0001-8494-732X
Easton, Douglas F.
Zheng, Wei
Kraft, Peter
Chang-Claude, Jenny
,
,
,
Article History
Received: 3 August 2020
Revised: 14 April 2021
Accepted: 28 April 2021
First Online: 2 August 2021
Ethics approval and consent to participate
: Collection of blood samples, urine samples and questionnaire information was undertaken with written informed consent and relevant ethical review board approval in accordance with the tenets of the Declaration of Helsinki (Supplementary Table InternalRef removed).
: Not applicable.
: Availability of lifetime smoking index GWAS described by Wootton et al.<sup>20</sup> Availability of self-reported cigarettes per day GWAS described by Liu et al.<sup>21</sup> Individual genotyping data from BCAC will not be made publicly available due to restraints imposed by the ethics committees of individual studies; requests for data can be made to the Data Access Coordination Committee of BCAC (ExternalRef removed). Summary results for all variants genotyped by BCAC are available at ExternalRef removed/.
: U.Me. has reported a conflict of interest outside of the submitted work (owing stocks in Abcodia awarded to her by University College London). P.H., R.M.T. and A.Cox. are subject editors for the <i>British Journal of Cancer</i>. P.D.P. P., E.J.S. and K.Cz. are editorial board members for the <i>British Journal of Cancer</i>. The remaining authors declare no competing interests.
: BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union’s Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community´s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2–2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l’Économie, Science et Innovation du Québec through Genome Québec and the PSR-SIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium was funded by U19 CA148065. The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the National Health and Medical Research Council, Australia. For the BCFR-NY, BCFR-PA, BCFR-UT, this work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government or the BCFR. For BIGGS, ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The BREast Oncology GAlician Network (BREOGAN) is funded by Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). CBCS is funded by the Canadian Cancer Society (grant # 313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire, de l’Alimentation, de l’Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and PI12/00070). The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398, UM1 CA164917 and U01 CA199277). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR 0707-10031. The GC-HBOC (German Consortium of Hereditary Breast and Ovarian Cancer) is supported by the German Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, Cologne). This work was also funded by the European Regional Development Fund and Free State of Saxony, Germany (LIFE-Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. Generation Scotland (GENSCOT) received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Funding for identification of cases and contribution to BCAC funded in part by the Wellcome Trust Seed Award “Temporal trends in incidence and mortality of molecular subtypes of breast cancer to inform public health, policy and prevention” Reference 207800/Z/17/Z. The GEPARSIXTO study was conducted by the German Breast Group GmbH. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). GLACIER was supported by Breast Cancer Now, CRUK and Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by the Rudolf Bartling Foundation. The HEBCS was financially supported by the Helsinki University Hospital Research Fund, the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HMBCS was supported by a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation. The HUBCS was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017), M.B. was supported by grant 17-44-020498, 17-29-06014 of the Russian Foundation for Basic Research, E.K was supported by the program for support the bioresource collections №007-030164/2, and the study was performed as part of the assignment of the Ministry of Science and Higher Education of the Russian Federation (№АААА-А16-116020350032-1). Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; 400413, 400281, 199600). LMBC is supported by the ‘Stichting tegen Kanker’. D.L. is supported by the FWO. The MABCS study is funded by the Research Centre for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects “5×1000”). The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The MEC was supported by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MISS study is supported by funding from ERC-2011-294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program—grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade—grant # PSR-SIIRI-701. The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research; the Research Council of Norway grant 193387/V50 (to A.-L. Børresen-Dale and V.N. Kristensen) and grant 193387/H10 (to A.-L. Børresen-Dale and V.N. Kristensen), South Eastern Norway Health Authority (grant 39346 to A.-L. Børresen-Dale) and the Norwegian Cancer Society (to A.-L. Børresen-Dale and V.N. Kristensen). The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grants U01CA164920 and U01CA167551 from the USA National Cancer Institute of the National Institutes of Health. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast Cancer Family Registry (BCFR) or the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organisations imply endorsement by the USA Government or the BCFR or CCFR. The Carolina Breast Cancer Study (NCBCS) was funded by Komen Foundation, the National Cancer Institute (P50 CA058223, U54 CA156733, U01 CA179715), and the North Carolina University Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107 and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The OBCS was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland (grant number 250083, 122715 and Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital-based research activities. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. The Two Sister Study (2SISTER) was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES102245), and, also by a grant from Susan G. Komen for the Cure, grant FAS0703856. SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation and the Swedish Research Council (VR 2017-00644) grant for the Swedish Infrastructure for Medical Population-based Life-course Environmental Research (SIMPL+++ER). The SZBCS was supported by Grant PBZ_KBN_122/P05/2004 and the program of the Minister of Science and Higher Education under the name “Regional Initiative of Excellence” in 2019-2022 project number 002/RID/2018/19 amount of financing 12 000 000 PLN. The TNBCC was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and MRC core funding (MR_UU_12023). The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Open Access funding enabled and organized by Projekt DEAL.